DXVX Signs 10.3 Billion KRW Healthcare Product Supply Contract in China
DXVX has entered into a supply contract worth 10.3 billion KRW for healthcare products with Hangzhou Guangcheng Enterprise Management Consulting Co., Ltd. This contract represents 22.11% of the company's recent revenue.
How this call is verified
▲ Bullish call was checked against the actual KOSPI price 24h later: — Flat (+0.00%, below the ±0.9% bar).
Bar: KOSPI ±0.9% within 24h · every verdict lands on the public ledger
AI comment — why bullish
DXVX has announced a significant supply contract for healthcare products to China, valued at approximately 10.3 billion KRW. This figure represents a substantial 22.11% of the company's most recent reported revenue, indicating a material impact on its financial performance. The counterparty, Hangzhou Guangcheng Enterprise Management Consulting Co., Ltd., operates within the bio-health industry, suggesting a strategic alignment. Investors should monitor the execution of this contract and any further details regarding the specific products and timelines. The success of this deal could signal DXVX's growing presence and capabilities within the Chinese market.
Market data
DXVX · 180400 · KOSDAQ →Previous-close data, updated T+1 · Source: Financial Services Commission of Korea via data.go.kr
Key takeaway
"DXVX Signs 10.3 Billion KRW Healthcare Product Supply Contract in China" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 75 out of 100. That score reflects how strongly the story is likely to move Bitcoin, US equities, the dollar, and gold, and near-duplicate coverage of the same event is clustered so only the representative article is scored. Reported by 금융감독원 전자공시(DART) on August 21, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 45.7%.